There are 2934 resources available
Optimal combination for firstline NSCLC
Presenter: Martin Reck
Session: Optimal delivery of immuno-oncology (I-O) in advanced NSCLC
Resources:
Slides
Webcast
Can we combine radiotherapy with I-O?
Presenter: Rafal Dziadziuszko
Session: Optimal delivery of immuno-oncology (I-O) in advanced NSCLC
Resources:
Slides
Webcast
HER2 overexpressing breast cancer
Presenter: Sherene Loi
Session: Novel therapeutic strategies in ABC: Immunotherapy, Antibody Drug Conjugates (ADCs) and beyond
Resources:
Slides
Webcast
Has molecular classification changed the medical approach in endometrial cancer?
Presenter: Carien Creutzberg
Session: Treating endometrial cancer in the molecular age
Resources:
Slides
Webcast
2411 - Polo-like Kinase 1 (PLK1) Inhibitor, Onvansertib, in Combination with Low-Dose Cytarabine or Decitabine in Patients with Relapsed/Refractory Acute Myeloid Leukaemia in Phase 1b
Presenter: Amer Zeidan
Session: Proffered Paper – Haematological malignancies & pediatric oncology
Resources:
Abstract
Slides
Webcast
3030 - The influence of TDM on achieving busulfan target exposure and related determinants, in both children and adults who underwent an allogeneic hematopoietic cell transplantation
Presenter: Jill Boss
Session: Proffered Paper – Haematological malignancies & pediatric oncology
Resources:
Abstract
Slides
Webcast
Endometrial cancer enters the immunotherapy era
Presenter: Mansoor Raza Mirza
Session: Treating endometrial cancer in the molecular age
Resources:
Slides
Webcast
Taking toxicity into account in the curative setting
Presenter: Nathan Cherny
Session: ESMO-MCBS: What have we learnt and how can we expand?
Resources:
Slides
Webcast
Challenges in grading based on disease free survival
Presenter: André Ilbawi
Session: ESMO-MCBS: What have we learnt and how can we expand?
Resources:
Slides
Webcast
2488 - Mutation tracking in circulating tumor DNA (ctDNA) detects minimal residual disease (MRD) in patients with localized colorectal cancer (CRC) and identifies those at high risk of recurrence regardless of stage, lack of CDX2 expression and CMS subtype.
Presenter: Noelia Tarazona Llavero
Session: Proffered Paper 1 – Gastrointestinal tumours, colorectal
Resources:
Abstract
Slides
Webcast